Najean Y, Pecking A, Broquet M
Nouv Rev Fr Hematol (1978). 1976 Jun;16(1):67-80.
Seventy-nine patients with a refractory anemia and partial myeloblastic medullary infiltration have been studied, according to a prospective common protocol. All the patients have been treated with androgens, at high dosage and for at least 10 months if surviving. This study enables to precise the natural history of the disease and to define some criteria valuable for the prognosis. It demonstrates that the classification of this clinical entity as a smoldering or pre-leukemia is justified: 63% of the patients died from acute myeloblastic leukemia. The disease is very severe: the median of survival from the diagnosis is only 13 months. Androgen therapy appears to have little if any effect on the anemia, granulocytopenia and thrombocytopenia; it does not seem to increase the patients' life expectancy.
按照一项前瞻性通用方案，对79例难治性贫血伴部分髓母细胞骨髓浸润患者进行了研究。所有患者均接受了雄激素治疗，剂量较高，且若存活至少治疗10个月。这项研究有助于明确该疾病的自然病程，并确定一些对预后有价值的标准。研究表明，将这种临床实体归类为冒烟型或白血病前期是合理的：63%的患者死于急性髓母细胞白血病。该疾病非常严重：从诊断开始计算的生存中位数仅为13个月。雄激素治疗似乎对贫血、粒细胞减少和血小板减少几乎没有影响；它似乎并未增加患者的预期寿命。
